ProMIS Neurosciences, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- ProMIS Neurosciences, Inc. is a clinical-stage biotechnology company focused on the discovery and development of next-generation therapeutic antibodies and vaccines targeting toxic misfolded proteins implicated in neurodegenerative diseases and other misfolded protein disorders. Its core products include PMN310, a humanized IgG1 monoclonal antibody targeting toxic amyloid beta oligomers for the treatment of Alzheimer's disease; PMN267, an antibody in preclinical development targeting misfolded TDP-43 for amyotrophic lateral sclerosis (ALS); PMN442, a monoclonal antibody targeting toxic alpha-synuclein oligomers and seeding fibrils for multiple system atrophy and related synucleinopathies; and PNM440, an alpha-synuclein vaccine for multiple synucleinopathies. The company also develops PMN311, an amyloid-beta vaccine candidate for Alzheimer's disease, and pursues therapies for frontotemporal lobar degeneration, Huntington’s disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. ProMIS applies proprietary computational platforms, including the EpiSelect™ engine, to predict and identify disease-specific epitopes on misfolded protein oligomers to develop targeted therapeutics. The company operates primarily in Canada and the United States and was founded in 2005, with headquarters in Toronto, Ontario. Recent major developments include advancing the PMN310 antibody through a Phase 1b clinical trial for Alzheimer’s disease, which is over 85% enrolled with cohorts 1 and 2 fully enrolled, showing a favorable safety profile and on track to report interim six-month data in Q2 2026 and top-line 12-month results in Q4 2026. The Data and Safety Monitoring Board has recommended progressing to the third and final dose escalation cohort of PMN310. In 2024 and 2025, ProMIS secured significant financing, including a $30.3 million private placement as part of up to $122.7 million in funding to support clinical development and general corporate purposes, and a $2.4 million PIPE financing in mid-2025. Additionally, in November 2025, the company executed a 1-for-25 reverse stock split to meet Nasdaq bid price requirements. These operational and financial advancements position ProMIS to deliver on its promise of developing disease-modifying therapies for Alzheimer’s, ALS, and synucleinopathies using its innovative epitope-targeting antibody and vaccine platform technology. The company actively participates in healthcare investor forums and continues its research collaborations and clinical development activities in North America.
Company News
ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September
Promis Neurosciences Q2 Earnings Call Highlights
ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights
Vertex Pharmaceuticals Inc (VRTX) (Q2 2026) Earnings Call Highlights: Revenue Surges 12% to $3.3 Billion, Driven by CF Portfolio and New Product Momentum
ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026
ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026
Promis Reports No ARIA-E in PMN310 Alzheimer's Trial Interim Data
Small-Cap ProMIS Neurosciences Says Lead Drug Shows Encouraging Action in Early Alzheimer's Study
ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer's Disease Trial
ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial
ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer's Disease
ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026
ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026
Wall Street Analysts See a 230.23% Upside in Promis Neurosciences (PMN): Can the Stock Really Move This High?
All You Need to Know About Promis Neurosciences (PMN) Rating Upgrade to Buy
Wall Street Analysts Think Promis Neurosciences (PMN) Could Surge 231.78%: Read This Before Placing a Bet
GMG Applies for Additional Environmental Approvals to Produce Graphene in USA
Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
ProMIS Neurosciences to Participate in Upcoming Conferences in June
ProMIS Neurosciences to Participate in Upcoming Conferences in June